228. Bronchiolitis obliterans
92 clinical trials,   125 drugs   (DrugBank: 34 drugs),   33 drug target genes,   152 drug target pathways

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00141726
(ClinicalTrials.gov)
October 200330/8/2005Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell TransplantSoluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II StudyLung Injury, Acute;Respiratory Distress Syndrome, Adult;Bronchiolitis ObliteransDrug: EtanerceptUniversity of Michigan Cancer CenterNULLCompleted6 YearsN/AAll34Phase 2United States
2NCT00029328
(ClinicalTrials.gov)
September 200110/1/2002Etanercept for Non-Infectious Lung Injury Following Bone Marrow TransplantationSoluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell TransplantationRespiratory Distress Syndrome, Adult;Bronchiolitis Obliterans;PneumoniaDrug: etanerceptFDA Office of Orphan Products DevelopmentNULLCompleted12 MonthsN/ABoth15Phase 1;Phase 2United States